To determine the optimal duration of high-intensity atorvastatin therapy post-acute coronary syndrome (ACS).
Summary:
A literature review was conducted using the MEDLINE database (1966-October 2013) and employing the search terms “atorvastatin OR statins AND myocardial infarction OR acute coronary syndromes.” Clinical trials in the English language with available abstracts were used to identify potential data sources. Four major trials evaluating atorvastatin 80 mg daily after an ACS were identified. The duration of follow-up ranged from 16 weeks to a median of 4.9 years. High-dose atorvastatin regimens were associated with a reduction in coronary events but also with higher rates of drug discontinuation due to adverse reactions. The benefit of high-dose atorvastatin has been sustained for at least 5 years.
Conclusion:
After an ACS, high-dose atorvastatin should be continued for at least 5 years. High-dose atorvastatin demonstrated a reduction in coronary events but dose reductions and higher discontinuation rates were also noted.
RogerVLGoASLloyd-JonesDM. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188–197.
2.
WrightRSAndersonJLAdamsCD, 2011ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):e215–e367.
3.
MukherjeeDFangJChetcutiS. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109(6):745–749.
4.
Gold Standard, Inc. Atorvastatin. Clinical Pharmacology [database online]. http://www.clinicalpharmacology.com. Accessed: February 10, 2014.
BrielMValeNSchwartzGG. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2012;158(1):93–100.
De LemosJABlazingMAWiviottSD. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA. 2004;292(11):1307–1316.
13.
LaRosaJCGrundySMWatersDD. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
14.
CannonCPBraunwaldEMcCabeCH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504.
15.
PedersenTRFaergemanOKasteleinJJ. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445.
16.
StoneNJRobinsonJLichtensteinAH. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25 suppl 2):S1–S45.
O’GaraPTKushnerFGAscheimDD, 2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;127(4):e362–e425. doi:10.1161/CIR.0b013e3182742cf6.
19.
SchwartzGGOlssonAGEzekowitzMD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718. doi:10.1001/jama.285.13.1711.
20.
PedersenTRCaterNBFaergemanO. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol. 2010;106(3):354–359.
21.
Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
